Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Technological barriers are affecting the participant response experience.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This retrospective, observational study will assess the health status of short- and long-term low-dose naltrexone (LDN) users.
Long-term (>5 years), intermediate-term (1-5 years), and short-term low-dose naltrexone (LDN) users (<12 months) will be contacted for a retrospective, observational assessment of their health status. Participants will be asked to complete a series of questionnaires assessing their quality of life, general physical and mental health, family history, the occurrence of age-related diseases, and immune status. Additionally, blood tests for immune and longevity markers will be optional for a subset of participants.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Long-term (>5 years) LDN users | Participants who have been using LDN for over 5 years |
| |
| intermediate-term (1-5 years) LDN users | Participants who have been using LDN for at least 1 year, but shorter than 5 years. |
| |
| short-term (<12 months) LDN users | Participants who have been using LDN for less than a year. This group will serve as the control group. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| low-dose naltrexone | Drug | LDN doses <20 mg/day |
|
| Measure | Description | Time Frame |
|---|---|---|
| Quality of life score | The short-form (SF)-36 Questionnaire generates scores in the categories: physical function, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health. Scores up to maximum 100, with higher scores representing better quality of life | At enrollment |
| Immune Status | Immune Status Questionnaire (ISQ) to define a measure of perceived immune status, consists of seven representative immune-associated symptoms and diseases. The Immune Status Questionnaire scores respondents out of 10, with 10 being a better outcome and lower scores worse outcome. | At enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| General health and family history | Standard questions assessing family history, and information about the dosing, duration of use, reasons for taking LDN, age, sex, weight, length, smoking and alcohol use history, substance abuse history, physical activity, other medications, and side effects of the drug, and other questions related to health and medical history. | At enrollment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Eligible long-term (>5 years), intermediate-term (1-5 years), and short-term (<12 months) LDN users
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sajad Zalzala, MD | AgelessRx | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AgelessRx | Ann Arbor | Michigan | 48104 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009271 | Naltrexone |
| ID | Term |
|---|---|
| D009270 | Naloxone |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006571 |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Levine's phenotypic age | Levine's phenotypic age will be calculated on basis of blood markers for age-associated diseases (glucoregulatory markers, lipids), as well as markers of inflammation | At enrollment |
| CD4/CD8 ratio | Peripheral blood CD4 vs CD8 T cell ratio in cells/mm3 | At enrollment |
| CMV IgG | Peripheral blood cytomegalovirus (CMV) IgG antibodies in U/mL | At enrollment |
| hsCRP | Peripheral blood human serum C-reactive protein (hsCRP) concentration in mg/L | At enrollment |
| IL-6 | Peripheral blood serum interleukin-6 (IL-6) concentration in pg/L | At enrollment |
| TNFÉ‘ | Peripheral blood serum tumor-necrosis factor alpha (TNFÉ‘) concentration in pg/L | At enrollment |
| Methylation age clock testing | DNA methylation array of a blood sample | At enrollment |
| Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |